What is Immy?
IMMY operates within the specialized field of mycology, dedicating its efforts to the development, manufacturing, and distribution of advanced diagnostic solutions for fungal diseases. With a history spanning over 45 years, the organization aims to enhance global healthcare standards by ensuring accessible and accurate diagnoses for conditions affecting over a billion people worldwide. IMMY's product portfolio includes a variety of tests such as lateral flow assays, enzyme immunoassays, and polymerase chain reaction (PCR) tests, designed for use by healthcare professionals across diverse clinical settings.
How much funding has Immy raised?
Immy has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
What's next for Immy?
The recent major strategic investment signifies a pivotal moment for Immy, likely enabling the company to accelerate its research and development initiatives, expand its manufacturing capabilities, and broaden its market reach. This capital infusion is expected to bolster Immy's efforts in combating the global challenge of fungal infections through enhanced diagnostic technologies. The company's established experience and commitment to innovation suggest a trajectory focused on solidifying its leadership in the mycology diagnostics sector and potentially exploring new therapeutic applications or partnerships.
See full Immy company page
